Lung Cancer

Rapid developments in the classification, screening and treatment of non-small-cell lung cancer (NSCLC) are improving outcomes for patients with the disease. This insightful guide is designed to bring you up to speed with recent advances, including: • the latest CT-based screening and interval growth imaging techniques • proposed changes to the TNM classification system • the increasing trend for minimally invasive and lung-sparing surgery • stereotactic radiation for early-stage tumors • new targeted therapies • breakthroughs in personalized medicine. Today's developments will change tomorrow's standards of care. 'Fast Facts: Non-Small-Cell Lung Cancer' is important reading for all health professionals and medical trainees working in this fast-moving area.

Carrying on the tradition established by its founding editor, the late Dr. Martin Abeloff, the 4th Edition of this respected reference synthesizes all of the latest oncology knowledge in one practical, clinically focused, easy-to-use volume. It incorporates basic science, pathology, diagnosis, management, outcomes, rehabilitation, and prevention – all in one convenient resource – equipping you to overcome your toughest clinical challenges. What's more, you can access the complete contents of this Expert Consult title online, and tap into its unparalleled guidance wherever and whenever you need it most! Equips you to select the most appropriate tests and imaging studies for diagnosing and staging each type of cancer, and manage your patients most effectively using all of the latest techniques and approaches. Explores all of the latest scientific discoveries' implications for cancer diagnosis and management. Employs a multidisciplinary approach - with contributions from pathologists, radiation oncologists, medical oncologists, and surgical oncologists - for well-rounded perspectives on the problems you face. Offers a user-friendly layout with a consistent chapter format • summary boxes • a full-color design • and more than 1,445 illustrations (1,200 in full color), to make reference easy and efficient. Offers access to the book's complete contents online – fully searchable – from anyplace with an Internet connection. Presents discussions on cutting-edge new topics including nanotechnology, functional imaging, signal transduction inhibitors, hormone modulators, complications of transplantation, and much more. Includes an expanded color art program that highlights key points, illustrates relevant science and clinical problems, and enhances your understanding of complex concepts.

Lung cancer remains a major cause of cancer deaths throughout the world. It is an extremely lethal neoplasm: 80-90% of patients who develop lung cancer will die of their disease. The purpose of this book is to update cancer specialists, pulmonary physicians, thoracic surgeons and general practitioners about the many recent advances in the treatment, prevention and biology of lung cancer. Despite the overall poor prognosis for patients, a number of new chemotherapeutic drugs and regimens have been developed which result in a clinically meaningful improvement in survival for patients with nonsmall cell lung carcinoma. Four chapters in this book are devoted to reviewing these new drugs and drug combinations (paclitaxel, docetaxel, vinorelbine, gemcitabine, topoisomerase inhibitors). Advances in the management of locally advanced nonsmall cell and small cell lung cancer are considered, including combined-modality treatments using chemotherapy, surgery, and radiation therapy. Results of recent trials involving chemoprevention agents are also reported. Finally, the latest progress in understanding the molecular biology of this disease, and how it might impact on the clinical management of lung cancer patients, is discussed.

Textbook of Lung Cancer, 2nd edition, published in association with the European Society of Medical Oncology, is a comprehensive and multidisciplinary text, which examines all aspects of this disease, with contributions from a multinational team of authors on etiology, epidemiology, molecular biology, pathology, smoking, detection and management, clinical features, staging and prognostic factors, surgery, radiotherapy and chemotherapy. It provides essential information and guidance for specialist trainees in oncology, and for the many physicians and specialists involved in the field of lung cancer.

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.

Among the deadliest type of cancers, lung cancer faces several challenges in diagnosis and treatment: late diagnosis and misdiagnosis, inadequate tumor sampling, and resistance development to current therapies, among others. Together with advances in the understanding of molecular features, factors, and mechanisms involved in initiation and tumor progression, important improvements have occurred in diagnostics and therapeutics in the shape of advances in molecular genotyping, procedures for sampling, new potential, and less invasive sources of samples for the diagnosis and development of new targeted therapies. The aim of this book is to provide an exciting read on strategies in the diagnosis and therapy of lung cancer.

Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer is an indispensable resource that will help pharmaceutical scientists and clinical researchers design and develop novel drug delivery systems and devices for the treatment of lung cancer. As recent breakthroughs in nanomedicine are now making it possible to deliver drugs, genes and therapeutic agents to localized areas of disease to maximize clinical benefit, while also limiting unwanted side effects, this book explores promising approaches for the diagnosis and treatment of lung cancer using cutting-edge nanomedical technologies. Topics discussed include polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles and nanoemulsions. Provides an overview of an array of nanotechnology-based drug delivery systems Examines the design, synthesis and application of different nanocarriers in drug and gene delivery Provides an in-depth understanding of the design of targeted nanotherapeutics and technologies and its implication in various site-specific cancers

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies. Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy. Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer. Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer. Features a new full-color design throughout, as well as updated diagnostic algorithms.

Get a quick, expert overview of the many key facets of lung cancer evaluation and management with this concise, practical resource by Drs. Lynn T. Tanoue and Frank Detterbeck. This easy-to-read reference presents a summary of today’s best evidence-based approaches to diagnosis and management in this critical area. Covers diagnosis and evaluation, treatment considerations, and comprehensive care options for patients with lung cancer. Provides insight on evidence for today’s best practices, as well as future directions in the field. Consolidates today’s evidence-based information on the clinical aspects of lung cancer into one convenient resource.

Advances in CT have enabled us to detect small lung cancers, which has changed the lung cancer surgery from lobectomy to a lesser lobar resection such as a segmentectomy or wedge resection. While wedge resection is a simple procedure, it has a higher risk of local recurrence of cancer than a lobectomy. On the other hand, segmentectomy is a well known curative surgery for small lung cancers. However, it is difficult to perform accurately because of its anatomical complexity, which makes surgeons hesitant to use it. The book “Illustrated Anatomical Segmentectomy for Lung Cancer” provides readers a detailed explanation of segmentectomy with numerous easy-to-understand color illustrations showing the precise segmental anatomies for each pattern of the procedure. To better illustrate an accurate anatomical segmentectomy, the text shows details of anatomy during segmentectomy. This can involve up to 25 patterns, each of which is shown in roughly 10 illustrations.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

Lung cancer is one of the most common cancers in both men and women worldwide. Early diagnosis of lung cancer can significantly increase the chances of a patient's survival, yet early detection has historically been difficult. As a result, there has been a great deal of progress in the development of accurate and fast diagnostic tools in recent years. Lung Cancer and Imaging provides an introduction to both the methods currently used in lung cancer diagnosis and the promising new techniques that are emerging. Areas covered include the major trends and challenges in lung cancer detection and diagnosis, classification of cancer types, lung feature extraction in joint PET/CT images, and algorithms in the area of low dosage CT lung cancer images.

What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on coping with emotions such as "smoker's guilt."

Lung cancer is the leading cause of cancer death in the United States, but IGRT (image guided radiation therapy) offers the possibility of more aggressive and enhanced treatments. The only available source on the subject that emphasizes new imaging techniques, and provides step-by-step treatment guidelines for lung cancer, this source helps clinici

The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms.

Tumors and Tumor-like Conditions of the Lung and Pleura is a superb visual resource that brings the state-of-the-art in thoracic diagnosis straight to the lab bench. Cesar A. Moran and Saul Suster are internationally recognized experts in pulmonary pathology who present a coherent and consistent approach to interpretation and diagnosis. Through more than 900 stunning photographs and a consistent, user-friendly format, this resource provides quality guidance on the diagnostic problems you face in everyday practice. You’ll get a host of innovative, practice-oriented features unavailable in any other text that streamline and facilitate diagnostic decision-making. Written by practitioners for practitioners, this visual resource is designed for quick and easy use. You can’t afford to be without it. Features over 900 high-quality full-color illustrations so you can recognize and diagnose any tissue sample under the microscope. Presents immunohistochemical and genetic features wherever relevant for comprehensive information on all of the investigative contexts important to formulating an accurate diagnosis. Includes summary tables throughout the text to simplify and clarify complex discussions and enable "at a glance" comparisons between entities. Provides practical advice from experts on pitfalls in differential diagnosis to help you avoid diagnostic errors.

Lung cancer affects millions of people worldwide and is the most common cause of cancer-related death in men. This volume investigates the biological basis of lung cancer, the risk factors involved, and recent advances in treatment strategies. Topics covered in this essential volume include: - Early Diagnosis and Screening for Lung Cancer - Targeting Epigenetics in Lung Cancer - Lung Cancer Metabolism - Stem Cell Biology and Lineage Plasticity - Application of Radiomics and AI for Lung Cancer Precision Medicine - Lung Cancer Computational Biology and Resources

Thoracic Malignancies: Thoracic Malignancies is the first title in Radiation Medicine Rounds. These tumors take more lives than any others and they are among the most preventable of tumors. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Thoracic Malignancies addresses the multi-disciplinary nature of the care of these tumors. There is representation from radiation oncology, medical oncology, and surgery ensuring a well-rounded summarization of current practice. Included are chapters on lung cancer, esophageal cancer, and thymomas providing coverage of the vast majority of thoracic tumors. The multi-disciplinary nature of the articles provides readers with an up-to-date summary and a well-rounded review regarding these tumors and their care. Expert authors provide reviews and assessments of the most recent data and its implications for current clinical practice, along with insights into emerging new trends of importance for the near future. About the Series Radiation Medicine Rounds is an invited review publication providing a thorough analysis of new scientific, technologic, and clinical advances in all areas of radiation medicine. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Radiation Medicine Rounds provides authoritative, thorough assessments of a wide range of Ïhot topicsÓ and emerging new data for the entire specialty of radiation medicine. Features of Radiation Medicine Rounds include: Editorial board of nationally recognized experts across the spectrum of radiation medicine In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Radiation Medicine Issues edited by an authority in specific subject area Focuses on major topics in Radiation Medicine with in-depth articles covering advances in radiation science radiation medicine technology, radiation medicine practice, and assessment of recent quality and outcomes studies Emphasizes multidisciplinary approaches to research and practice

Lung cancer is the leading cause of cancer-related death among men and women in the U.S. and worldwide. For many decades, lung cancer was the sole cancer among the deadly four without an evidence-based screening method for decreasing mortality. This changed in November 2011, when findings from the National Lung Cancer Screening Trial showed low-dose lung CT screening was more efficacious in reducing deaths in high-risk individuals than conventional radiography. As such, an ever-increasing number of health organizations now recommend this screening protocol. Lung Cancer Screening by Mark Parker and esteemed VCU Health colleagues, fulfills the dire need for a comprehensive guide explaining the crucial aspects of lung cancer screenings. The first two chapters lay a foundation with discussion of lung cancer epidemiology and risk factors beyond cigarette smoking. Subsequent chapters cover the fundamentals, with clinical pearls on setting up a successful lung cancer screening program, patient eligibility criteria, imaging variances of tumors in the lungs, screening pros and cons, and interpreting/reporting screening results. The evolution and future of lung cancer screenings Detection and management of unexpected incidental pulmonary and non-pulmonary findings Discussion of test cases utilizing the Lung-RADSTM risk-stratifying system for low-dose chest CT screenings Benefits and potential harms associated with mass lung cancer screening programs including false positive, false negative, and over-diagnosis rates This state-of-the-art guide is essential reading for radiologists, oncologists, pulmonologists, and internists. It is a must-have bookshelf reference for hospital radiology and oncology departments, in particular for those setting up new lung cancer screening programs.